Q-Sera’s innovative blood clotting technology granted patent in US

Medical device company Q-Sera Pty Ltd today announces that it has received a Notice of Allowance from the United States Patent & Trademark Office for the foundation patent of its innovative blood clotting technology for use in blood collection tubes.

The Q-Sera technology is based on lead active RAPClot® which has been shown to rapidly produce high quality serum for biochemical analysis, even if the blood sample contains anti-coagulants. The ability to clot all blood samples in less than five minutes, including those containing anti-coagulants which affect around 10 percent of hospital patients, make the technology a game changer.

In acute situations where speed matters such as emergency departments, blood tests are commonly used to assist the accurate diagnosis of medical problems ranging from heart attacks to diabetes. A delay in test results means a delay in diagnosis and the right care for very sick patients. Having access to a technology that universally clots all blood samples within 5 minutes will contribute to improved patient outcomes and reduced healthcare costs.

“Q-Sera is delighted with this tremendous milestone, as it underlines the value of our technology as a ‘universal’ blood collection tube to produce high-quality serum. The issued patent provides protection through 2030 in the United States, which is a key market for us,” says Q-Sera CEO Michael Grant.

Q-Sera’s technology now has patent protection for use in blood collection tubes in the United States, Europe, Japan, China, Mexico, Russia, Canada, South Africa and Australia. Q-Sera is progressing additional patents to cover novel formulations and expanded uses for its unique actives, extending the commercial opportunities.